Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype

Thomas Chatzikonstantinou¹, Christos Demosthenous¹ and Panagiotis Baliakas²,³*

¹Hematology Department—Bone Marrow Transplantation (BMT) Unit, G. Papanicolaou Hospital, Thessaloniki, Greece,
²Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden,
³Department of Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden

Several reports highlight the clinical significance of cytogenetic complexity, namely, complex karyotype (CK) identified though the performance of chromosome banding analysis (CBA) in chronic lymphocytic leukemia. Indeed, apart from a number of studies underscoring the prognostic and predictive value of CK in the chemo(immune)therapy era, mounting evidence suggests that CK could serve as an independent prognosticator and predictor even in patients treated with novel agents. In the present review, we provide an overview of the current knowledge regarding the clinical impact of CK in CLL, touching upon open issues related to the incorporation of CK in the clinical setting.

Keywords: CLL (chronic lymphocytic leukemia), prognosis, prediction, high-risk, complex karyotype (CK), cytogenetic complexity

INTRODUCTION

Chronic lymphocytic leukemia (CLL) is the most common hematological malignancy among the elderly in the western world, characterized by clonal growth of mature, CD5+ B lymphocytes in the bone marrow, peripheral blood, and secondary lymphoid organs (1). The clinical course of CLL is extremely variable, ranging from asymptomatic to highly aggressive, which likely reflects the underlying biological heterogeneity (2). A great number of clonal- and patient-related features with prognostic and/or predictive value have been identified over the last decades, in an effort to optimize the management of CLL (3–9).

Aberrations detected with Fluorescence in situ hybridization (FISH), namely the Döhner hierarchical model, have for the last 20 years served as the backbone of CLL diagnostics, dictating the treatment choice, together with the mutation status of TP53 gene and also the segregation into mutated- and unmutated-CLL (M-CLL and U-CLL respectively) (10, 11). Nevertheless, FISH analysis cannot provide a comprehensive overview of the genomic background of the clone, something that can be accomplished with other methodologies, such as chromosome-banding analysis (CBA), chromosome microarray analysis (CMA) or genome-wide analysis (12–14). A major advantage of these methods, especially CBA, is the identification of complex karyotype (CK) which according to recent reports is a significant prognostic feature with the potential of becoming also a novel predictive biomarker (4, 15). A number of methodological issues, mainly the obtainment of adequate number of representative metaphases, have been overcome with the application of specific culture protocols, making CBA a robust and reproducible method (16–18).
In CLL similarly to other hematological malignancies, CK is defined by the presence of ≥3 numerical or structural abnormalities in ≥2 metaphases in the same clone. CK is reported in 10–20% of untreated patients with CLL and in 8% of patients with monoclonal B lymphocytosis (MBL) (4, 15, 18, 19). The association of CK with advanced-stage disease, U-CLL, TP53 mutations, adverse FISH abnormalities (del(17p) and/or del(11q)), and telomere dysfunction (15, 20), suggests a potential role of chromosomal aberrations early in the disease development. CK development has been proposed to arise in a 4-phase process in U-CLL: enhanced response of lymphocytes to antigens leading to stimulation of intracellular B-cell-receptor (BCR) signaling and proliferation; telomere shortening during each cell division to a critical point; inactivation of genes implicated in DNA repair (e.g., TP53, ATM), ubiquitin-mediated degradation of oncoproteins (e.g., FBXW7), and to the inflammatory pathway (e.g., MYD88) and; increased genomic instability and risk of chromosome break events (21).

In the present review, we focus on the prognostic and the predictive value of CK in CLL, while we further discuss future perspectives regarding the potential role of CK in the management of CLL as well as issues related to the applied methodology and interpretation of eventual findings.

**PROGNOSTIC SIGNIFICANCE OF CK IN CLL**

The prognostic value of CK in CLL has been mainly assessed in retrospective studies of both untreated and treated patients, mostly in the era of chemo(immune)therapy. Juliusson et al. first reported that patients with indolent lymphomas (including CLL) and three or more cytogenetic aberrations exhibited dismal clinical outcome compared to patients with normal karyotype (22). In a later CLL-specific cohort, it was reported that three or more aberrations, were linked to shorter overall survival (OS), while specific structural abnormalities, such as aberrations involving 14q32 and trisomy 12 correlated with worse prognosis (23, 24). The advent of specific culture protocols with the addition of mitogens, namely CD40 ligand (CD40L) or CpG-oligonucleotide DSP30 plus interleukin-2 (IL-2) allowed the performance of large cytogenetic studies that further highlighted the association between CK and inferior clinical outcome in CLL. Mayr et al. reported that patients with CLL and CK had a shorter treatment free survival (TFS) and OS compared with patients with fewer aberrations, especially if accompanied by the presence of translocations (25). In a seminal study including 506 patients with CLL, CK was detected in 16% of the cohort, while interestingly paired analysis with FISH indicated that the two methods complement each other and that their combination provides a far more comprehensive genetic characterization than each assay alone (26).

Despite not being part of the standard diagnostic algorithm in CLL, several institutions included CBA in the CLL work up. This approach allowed the performance of the first large scale retrospective study with the inclusion of 1,001 patients with CLL, where CK was reported in 16% of the cohort at the time of CLL diagnosis (15). Furthermore, CK was, as in previous studies, associated with U-CLL, high expression of CD38, del (11q) and del(17p), while it was also an independent prognosticator for shorter time to first treatment (TTFT) and OS. In addition, it was suggested that the presence of ≥5 aberrations correlated with an even worse clinical outcome, however, the number of the patients in that subgroup was relatively low precluding from definite conclusions. Interestingly, the impact of CK was not affected by the presence of translocations, neither balanced nor unbalanced.

In a cohort with fewer patients, Rigolin et al. reported that the coexistence of CK and unbalanced rearrangements was associated with inferior TTFT and OS. In that study though, cases with CK and unbalanced rearrangements were enriched for TP53 aberrations (deletion and/or mutation). That said the negative impact of unbalanced rearrangements was independent of TP53 status (27). The association of TP53 status and CK was further evaluated by Puiggros et al. (28), who within a cohort of 1,045 patients with CLL detected 99 (10%) with CK. Once more, CK was associated with del (17p) and del(11q) [del(17p) and del(11q) defined as high-risk (HR) FISH], as well as with shorter TTFT and OS. Patients with CK and HR FISH exhibited the worst overall prognosis. However, the clinical outcome of patients with CK was not affected by the presence of HR-FISH, suggesting that other clinicobiological features than TP53 status may also contribute to the poor prognosis of CK with CL.
it is still unclear if CK is indeed an independent predictor for patients treated with chemo(immune)therapy or the reported effect of CK is the result of a joint impact of CK and other unfavorable biomarkers, namely TP53 aberrations and U-CLL.

The predictive value of CK in CLL becomes even more relevant as the treatment of CLL is shifting drastically towards novel agents, i.e., B cell signaling kinase inhibitors and the Bcl-2 inhibitor venetoclax. Several studies have attempted to address this issue in the context of clinical trials and assess the potential utility of CBA as a predictive factor. Interestingly, cytogenetic complexity has been even assessed with the advent of CMA. In the great majority of these studies, CK was considered as one homogeneous group, defined by the presence of ≥2 cytogenetic abnormalities without taking into account the differentiation to low-CK, intermediate-CK and high-CK (Table 1).

Ibrutinib-mono-therapy, both in treatment-naïve and relapsed/refractory (R/R) CLL patients, demonstrated an overall response rate of approximately 90% (39). The presence of CK was associated with shorter duration of response [DOR, 31 months vs. not reached (NR)], PFS (31 months vs. NR), and median OS (54 months vs. NR) compared to patients with ≤2 cytogenetic aberrations (non-CK) (34, 39). That said, survival in R/R patients with CK appeared to be significantly influenced by the coexistence of del(17p) which was associated with decreased overall response rate (ORR, 82% vs. 100%; DOR, 23 vs. 53 months), PFS (25 vs. 55 months), and OS (32 months vs. NR).

Interestingly, a follow-up of the RESONATE study, a randomized comparison of ibrutinib to ofatumumab in R/R patients with CK appeared to be significantly influenced by the coexistence of del(17p) which was associated with decreased overall response rate (ORR, 82% vs. 100%; DOR, 23 vs. 53 months), PFS (25 vs. 55 months), and OS (32 months vs. NR).

A randomized, double-blind, phase 3 study assessing the efficacy of idelalisib in combination with rituximab (IR) in patients with relapsed CLL and significant comorbidities, showed that IR provided ORR of 81 and 89% in CK and non-CK groups, respectively (38). An extended study was designed to elucidate further the efficacy of IR in the presence of CK. Around 60% of patients with CK carried also TP53 aberrations compared to 43% of patients without CK. The median OS was prolonged in the CK-group treated with IR [median: 28.3 (range 16.6, NR) months], compared to patients with CK who received placebo/rituximab [median: 9.2 (range: 2.0, 53.5) months]. Of note, co-existence of CK and TP53 aberrations or del(11q) did not significantly affect survival in patients who received IR. That said, solid conclusion cannot be drawn since the sample size was small while the methodology for the detection of CK was not uniform (36).

Regarding venetoclax-based regimens, a 4-year clinical follow-up of MURANO study explored the predictive value of cytogenetic complexity in R/R CLL patients treated with

| Study | Number of patients | Type of treatment | Line of treatment | Definition of CK | PFS/OS | Comment |
|-------|-------------------|-------------------|-------------------|-----------------|--------|---------|
| Brown et al. (34) | Total: 195 | Ibrutinib | ≥ 2nd line | ≥ 3 cytogenetic abnormalities | 18-mo PFS: 72% | PFS with Ibrutinib was similar regardless of the presence of CK. |
| | CK: 39 | Ofatumumab | | | 18-mo PFS: 0% | |
| Woyach et al. (35) | Total: 166 | Ibrutinib ± Rituximab | 1st line | ≥ 3 cytogenetic abnormalities | NA | CK did not influence Ibrutinib-induced PFS in 1st line, HR = 1.01 (95% CI 0.68-1.51, p = 0.95) |
| | CK: 44 | Bendamustine plus Rituximab | | | | In the Ibrutinib plus Rituximab arm, no significant difference in OS was noted between patients with or without CK. |
| Kreuzer et al. (36) | Total: 127 | Ibrutinib plus Rituximab | ≥ 2nd line | ≥ 3 cytogenetic abnormalities | Median OS: 28.3 [16.6, NR] months | |
| | CK: 50 | Rituximab | | | Median PFS: 20.9 [8.5, NR] months | |
| Kater et al. (37) | Total: 288 | Venetoclax plus placebo | ≥ 2nd line | low-GC: ≥ 3 genomic abnormalities, high-GC: ≥ 5 genomic abnormalities | Median OS: 9.2 [16.6, NR] months | |
| | low-GC: 63 | Venetoclax plus Rituximab | | | NA | |
| | high-GC: 31 | Bendamustine plus Rituximab | | | | |
| Al-Sawaf et al. (38) | Total: 397 | Venetoclax plus Obinutuzumab | 1st line | ≥ 3 cytogenetic abnormalities | 2 year-PFS: 78.9% | Venetoclax plus Obinutuzumab showed similar PFS and OS rates in patients with and without CK. |
| | CK: 64 | Chlorambucil plus Obinutuzumab | | | 2 year-PFS: 36.6% | |

CK, complex karyotype; GC, genomic complexity; OS, overall survival; PFS, progression free survival.
venetoclax–rituximab (VenR) or bendamustine–rituximab (BR) (37). The authors followed the segregation in low-, intermediate- and high-Ck, with the advent of MCA. Patients with non-Ck demonstrated better PFS than those with either low-Ck or high-Ck status (HR, 2.0; 95% CI, 1.4 to 6.3; p = 0.025 and HR, 2.9; 95% CI, 1.1 to 3.6; p = 0.0057, respectively). Additionally, patients with high-Ck showed a trend towards worse PFS versus those with fewer abnormalities (HR, 1.5; 95% CI, 0.7 to 3.4; p = 0.29).

The role of Ck in venetoclax-based combination was also assessed in treatment-naïve patients following therapy with venetoclax–obinutuzumab (VenG) or chlorambucil–obinutuzumab (ClbG) within the CLL14 trial (38). Not surprisingly, 32% of patients with Ck carried also TP53 aberrations contrasting non-Ck patients, (8%). U-CLL was present in similar proportions of patients with Ck and non-Ck. VenG was associated with significantly better responses independently of the presence of Ck with ORRs of 82.4 and 87.3% (p= 0.42) for patients with Ck and non-Ck respectively. The complete eradication of the leukemic cells is a desired endpoint in CLL management usually translating in a better outcome (41–43). In the VenG arm, the rates of undetectable MRD (uMRD) were similar between patients with Ck and non-Ck in the peripheral blood (79.4% vs 77.1%; p = 1.0) and in the bone marrow (58.8% vs. 57.8%, p = 1.0). These high uMRD-rates were reflected into non-statistically significant differences between those groups in PFS (median, NR; 2-year-PFS rate, 78.9 and 91.1%, respectively; HR, 1.909; 95% CI, 0.806–4.520) and OS (median, NR; 2-year-OS rate, 88.2 and 93.2%; HR, 1.511; 95% CI, 0.496–4.600). Interestingly, no difference was neither observed within the Ck cohort when the level of cytogenetic complexity was taken into consideration, with the number of aberrations (≥5 or ≤5) not having any impact on clinical outcome. That said the number of patients with ≥5 aberrations was extremely low. Finally, TP53 aberrations did not have any impact on the outcome of patients with Ck treated with VenG.

**DISCUSSION**

As the concept of precision medicine becomes part of the routine-management of CLL, the need for identifications of biomarkers, which may guide treatment choices, is imperative. These markers should be solid, reproducible and highly specific to the available treatment alternatives. Until today, TP53 aberrations and the somatic hypermutation status of the immunoglobulin heavy variable genes (IGHV) are the main disease-related features that shape the treatment algorithm in CLL. Several other genetic abnormalities have been associated with distinct clinical outcomes without however being incorporated in the clinical praxis. Ck is a novel candidate biomarker that seems to be of significance regarding prognosis, but more importantly prediction, even in the era of the novel agents. However, several issues need to be further addressed before Ck can be integrated in the clinical setting.

For many years, there were concerns regarding the applied methodology for the detection of Ck. Today there is no doubt that with the advent of specific culture protocols, i.e., the addition of mitogens, CBA is a robust and reproducible methodology in CLL, and therefore, the obtained karyotypes are fully trustworthy and representative of the CLL clone. However, it is still unclear whether CMA can replace CBA and serve as a surrogate method for the detection of cytogenetic complexity. Indeed, CMA can be informative regarding the grade of complexity but adoption of definitions based on CBA, namely, low-Ck vs high-Ck should be followed with caution as the two methodologies have a number of differences that may affect their output.

When it comes to prognosis in cancer, it is highly common to apply prognostic indices, which are generated after the performance of statistical analysis taking into account a number of clinical and biological features. CLL is no exception (6). Over the years, numerous prognostic indices have been proposed. Nevertheless, their clinical utility has been questioned, since their actual applicability is limited (44, 45). Ck has not thus far been assessed within the context of a prognostic index, mainly due to missing cytogenetic data for the great majority of the patients that have been included in such studies. Whether, the implementation of Ck in the generation of prognostic indices has the potential to improve their applicability is still unknown.

Another issue that remains open is whether Ck is indeed independent of other high-risk features mainly TP53 aberrations and U-CLL. Undoubtedly, patients with Ck are enriched for TP53 aberrations and U-CLL with that enrichment reaching higher rates as the number of cytogenetic aberrations increases. That said, high-Ck is even present in M-CLL as well as in patients without TP53 aberrations retaining its prognostic value. Therefore, the traditional claim that Ck and TP53 aberrations always co-exist seems not to be true. Of note, in a meaningful proportion of CLL with Ck, the presence of TP53 aberrations has been excluded even with the performance of highly sensitive methodologies that allow the detection of even small TP53 clones. One could therefore suggest that at least within a number of patients with Ck, genomic instability could be independent of p53 biology. Coming to the interaction of Ck and U-CLL, there are still many unaddressed issues. In general, U-CLL is associated with high-risk genetic features with Ck being no exception. However, Ck has been reported even within M-CLL where it seems to be associated with worse clinical courses. This notion however does apply in all M-CLL since specific cytogenetic aberrations seem to overcome the negative impact of cytogenetic complexity. A typical example is M-CLL with Ck carrying +12,+19, a subgroup accounting for 1-2% of all CLL that exhibits extremely indolent clinical behavior irrespectively of the grade of cytogenetic complexity (4).

In the context of clinical trials, the data regarding the impact of Ck are still scarce, since the number of included cases is extremely low and therefore any extrapolation is quite uncertain. Therefore, more studies are needed in order to reach solid conclusions regarding the predictive value of Ck. Nevertheless, the low number of high-Ck (5%) at least at front-line treatment underscores the need for large population-studies, since it will be difficult to recruit the required number of patients with high-Ck.
REFERENCES

1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016
   Revision of the World Health Organization Classification of Lymphoid
   Neoplasms. Blood (2016) 127(20):2375–90. doi: 10.1182/blood-2016-01-643569
2. Burger JA. Treatment of Chronic Lymphocytic Leukemia. *New Engl J Med*
   (2020) 383(5):460–73. doi: 10.1056/NEJMr1908213
3. Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti
   M, et al. Clinical Effect of Stereotyped B-Cell Receptor Immunoglobulins in
   Chronic Lymphocytic Leukaemia: A Retrospective Multicentre Study. *Lancet
   Haematol* (2014) 1(2):74–84. doi: 10.1016/S2353-3026(14)00005-2
4. Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, et al.
   Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions,
   Associations, and Clinical Impact. *Blood* (2019) 133(11):1205–16. doi: 10.1182/
   blood-2018-09-873083
5. Ljungstrom V, Baliakas P. Prognostic and Predictive Implications of
   Cytogenetics and Genomics. *Hematol Oncol Clin North Am* (2021) 35
   (4):703–13. doi: 10.1016/j.hoc.2021.04.002
6. Baliakas P, Mattsson M, Stamatoopoulos K, Rosenquist R. Prognostic Indices
   in Chronic Lymphocytic Leukaemia: Where do We Stand How do We
   Proceed? *J Internal Med* (2016) 279(4):347–57. doi: 10.1111/jim.12455
7. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, et al.
   Recurrent Mutations Refine Prognosis in Chronic Lymphocytic Leukemia.
   *Leukemia* (2015) 29(2):329–36. doi: 10.1038/leu.2014.196
8. Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis
   A, et al. Tailored Approaches Grounded on Immunogenetic Features for
   Refined Prognostication in Chronic Lymphocytic Leukaemia. *Haematologica*
   (2019) 104(2):360–9. doi: 10.3324/haematol.2018.195032
9. Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-
   Subero JH, et al. Non-Coding Recurrent Mutations in Chronic Lymphocytic
   Leukaemia. *Nature* (2015) 526(7574):519–24. doi: 10.1038/nature14666
10. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner
    H, et al. Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic
    Leukemia: A Report From the International Workshop on Chronic
    Lymphocytic Leukemia Updating the National Cancer Institute-Working
    Group 1996 Guidelines. *Blood* (2008) 111(12):5446–56. doi: 10.1182/blood-
    2007-06-093906
11. Dohner H, Stilgenbauer S, Döhner K, Bentz M, Lichter P. Chromosomal
    Aberrations in B-Cell Chronic Lymphocytic Leukemia: Reassessment Based
    on Molecular Cytogenetic Analysis. *J Mol Med (Berl)* (1999) 77(2):266–81.
    doi: 10.1007/s001090050530
12. Ramos-Campoy S, Puiggros A, Bea S, Bougeon S, Larrazabal J, Costa D, et al.
    Chromosome Banding Analysis and Genomic Microarrays are Both Useful
    But Not Equivalent Methods for Genomic Complexity Risk Stratification
    in Chronic Lymphocytic Leukemia Patients. *Haematologica* (2021). doi:
    10.3324/haematol.2020.274456
13. Leeksa AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, van der Keiwe-
    Kersemaekers AM, et al. Genomic Arrays Identify High-Risk Chronic

In conclusion, CK is a strong prognostic marker in CLL, while its predictive value remains unclear, especially in the era of novel agents.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

ACKNOWLEDGMENTS

This study was supported in part by the Lion’s Cancer Research Foundation, Uppsala.
26. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive Genetic Characterization of CLL: A Study on 506 Cases Analyzed With Chromosome Banding Analysis, Interphase FISH, IgVH Status and Immunophenotyping. *Leukemia* (2007) 21(12):2442–51. doi: 10.1038/sj.leu.2404935

27. Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro I, Zaggari B, et al. In Chronic Lymphocytic Leukaemia With Complex Karyotype, Major Structural Abnormalities Identify a Subset of Patients With Inferior Outcome and Distinct Biological Characteristics. *Br J Haematol* (2018) 181(2):229–33. doi: 10.1111/bjh.15174

28. Puiggros A, Collado R, Calasanz MJ, Ortega M, Ruiz-Xiville N, Rivas-Delgado A, et al. Patients With Chronic Lymphocytic Leukaemia and Complex Karyotype Show an Adverse Outcome Even in Absence of TP53/ATM FISH Deletions. *Oncotarget* (2017) 8(33):34297–303. doi: 10.18632/oncotarget.17350

29. Baliakas P, Puiggros A, Xochelli A, Sutton LA, Nguyen-Khac F, Gardiner A, et al. Additional Trisomies Amongst Patients With Chronic Lymphocytic Leukemia Carrying Trisomy 12: The Accompanying Chromosome Makes a Difference. *Haematologica* (2016) 101(7):e299–302. doi: 10.3324/haematol.2015.140202

30. Ibbotson R, Athanasiadou A, Sutton LA, Davis Z, Gardiner A, Baliakas P, et al. Coexistence of Trisomies of Chromosomes 12 and 19 in Chronic Lymphocytic Leukaemia Occurs Exclusively in the Rare IgG-Positive Variant. *Leukemia* (2012) 26(1):170–2. doi: 10.1038/leu.2011.186

31. Fox R, Del Giudice I, Cuneo A, Del Poeta G, Ciocchi S, Di Raimondo F, et al. Chlorambucil Plus Rituximab With or Without Maintenance Rituximab as First-Line Treatment for Elderly Chronic Lymphocytic Leukemia Patients. *Am J Hematol* (2014) 89(5):493–6. doi: 10.1002/ajh.23668

32. Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, et al. The Combination of Complex Karyotype Subtypes and IGHV Mutational Status Identifies New Prognostic and Predictive Groups in Chronic Lymphocytic Leukaemia. *Br J Cancer* (2019) 121(2):150–6. doi: 10.1038/s41416-019-0500-x

33. Herling CD, Klaumunzer M, Rocha CK, Altmuller J, Thiele H, Bahlo J, et al. In Chronic Lymphocytic Leukaemia With Complex Karyotype Subtypes and IGHV Mutational Status and Distinct Biological Characteristics. *Am J Hematol* (2012) 26(1):170–2. doi: 10.1038/leu.2011.186

34. Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre SE, et al. Complex Karyotype and Chronic Lymphocytic Leukemia. *Blood* (2020) 135(11):8667–670. doi: 10.1182/blood.2019003451

35. O’Brien S, Furman RR, Coutre S, Rimm JW, Burger JA, Blum K, et al. Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience. *Blood* (2018) 131(17):1910–9. doi: 10.1182/blood-2017-10-810044

36. Kreuzer KA, Furman RR, Coutre SE, Cheson BD, Pagel IM, Hillmen P, et al. Ibrutinib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. *New Engl J Med* (2014) 370(11):997–1007. doi: 10.1056/NEJMoa1315262

37. Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. *J Clin Oncol Off J Am Soc Clin Oncol* (2016) 34(31):3758–65. doi: 10.1200/ICO.2016.67.1305

38. Bottcher S, Rigten M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal Residual Disease Quantification is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukaemia: A Multivariate Analysis From the Randomized GCCLLSG CLL8 Trial. *J Clin Oncol Off J Am Soc Clin Oncol* (2012) 30(9):980–8. doi: 10.1200/ICO.2011.36.9348

39. Bottcher S, Hallek M, Rigten M, Kneba M. The Role of Minimal Residual Disease Measurements in the Therapy for CLL: Is it Ready for Prime Time? *Hematol Oncol Clin North Am* (2013) 27(2):267–88. doi: 10.1016/j.hoc.2013.01.005

40. Molica S, Giannarelli D. Prognostic Models for Chronic Lymphocytic Leukaemia (CLL): A Systematic Review and Meta-Analysis. *Leukemia* (2021) 35(2):615–8. doi: 10.1038/s41373-020-0924-8

41. Kreuzberger N, Damen JA, Trivella M, Estcourt LJ, Aldin A, Umlauf L, et al. Prognostic Models for Newly-Diagnosed Chronic Lymphocytic Leukaemia in Adults: A Systematic Review and Meta-Analysis. *Cochrane Database Syst Rev* (2020) 7(CD012022). doi: 10.1002/14651858

42. Kittai AS, Miller CR, Goldstein D, Huang Y, Abruzzo LV, Beckwith KA, et al. The Impact of Increasing Karyotypic Complexity and Evolution on Survival in CLL Patients Treated With Ibrutinib. *Blood* (2021). doi: 10.1182/blood.2020010536

**Conflict of Interest:** PB has received honoraria from Abbvie, Gilead, Janssen, and research grants from Gilead.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Chatzikonstantinou, Demostenous and Baliakas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.